Special Issue

Genetic and Genomic Biomarkers in Cancer Diagnosis, Prognosis, and Treatment Prediction

Message from the Guest Editor

Advances in cancer genetics and genomics are expanding the opportunities for utilizing genetic and genomic biomarkers in cancer diagnosis, prognosis. and treatment prediction. Cancer genetic and genomic tests typically analyze nucleic acid-based biomarkers and can be categorized based on their clinical applications: diagnostic, prognostic, and predictive. Diagnostic tests are used for cancer screening, diagnosis, subtyping, and staging. Prognostic tests provide insights into the natural progression of cancer and potential outcomes. In contrast, predictive tests offer information about how likely a patient is to respond to a specific drug or therapy. Importantly, a single genetic or genomic test may serve multiple purposes depending on the clinical context. The role of these tests in clinical management is expected to grow continuously. This approach enhances the accuracy of diagnoses, spares patients from ineffective treatments, and minimizes side effects, ultimately leading to more personalized and precise cancer management.

Guest Editor

Prof. Dr. Jianli Dong

Department of Pathology, Sealy Center for Cancer Cell Biology, University of Texas Medical Branch, 5.202 John Sealy Annex, 301 University Boulevard, Galveston, TX 77555, USA

Deadline for manuscript submissions

31 December 2025



Diagnostics

an Open Access Journal by MDPI

Impact Factor 3.3 CiteScore 5.9 Indexed in PubMed



mdpi.com/si/227521

Diagnostics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
diagnostics@mdpi.com

mdpi.com/journal/diagnostics





Diagnostics

an Open Access Journal by MDPI

Impact Factor 3.3 CiteScore 5.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

You are cordially invited to submit research articles, short communications, comprehensive reviews, case reports or interesting images for consideration and publication in *Diagnostics* (ISSN 2075-4418). *Diagnostics* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Andreas Kjaer

Department of Clinical Physiology, Nuclear Medicine & PET National University Hospital, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, DK-2100 Copenhagen, Denmark

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, Inspec, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Internal Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).

